The trajectory of companies tied to the drug's history presents a complex investment picture . While the initial boom generated substantial returns , generic alternatives have significantly impacted market share . Investing in related pharmaceutical firms now requires a discerning assessment of proprietary safeguards, evolving medical changes, and